Coherentmarketinsightsus

  Cholangiocarcinoma The diagnosis of cholangiocarcinoma is challenging because most cases of the disease are diagnosed late. A cholangioscopy can reveal the presence of a tumor. However, a cholangiogram is a suggestive test and further diagnostic testing may be needed. In addition, because this cancer is difficult to detect, it is important to see a gastroenterologist if they have any symptoms of the disease. Unfortunately, Cholangiocarcinoma has a poor prognosis because it does not present symptoms until the late stages. Despite this, surgical treatment is a viable option for patients with this cancer. Surgical resection is usually required for early-stage cholangiocarcinoma. The procedure can help patients survive for up to five years. For advanced stages of the disease, chemotherapy is a common option, but it has a very low survival rate. Surgery is the only cure for cholangiocarcinoma, although it is only available when cancer has spread to other tissues. A bile duct can ...

  Cancer Supportive Care Products can be defined as products or drugs which are mainly useful for treatment of undesireable effects connected with cancer therapy in addition to for treatment of symptoms and signs of cancer such nausea, vomiting, hair thinning, low blood counts, and others. The Cancer Supportive Care Products could be classified on the inspiration of drug class that will be further categorised into monoclonal antibodies, opioid analgesics, nonsteroidal erythropoietin stimulating agents, anti-infective drugs, granulocyte colony stimulating factor, anti-emetics drugs, bisphosphonates, and anti-inflammatory drugs. Moreover, entry of biosimilars can be expected to limit growth of the global cancer supportive care products market. Patents for many major drugs used in cancer supportive care products have expired or are expected to expire in the near future. This really is projected to open the gateway for biosimilars for anti-cancer therapy, which wo...